Objective: Extremely low gestational age neonates (ELGANs) are at risk for pulmonary hypertension (PH). We hypothesized that PH, defined by echocardiogram at 36 weeks gestational age (GA), would associate with respiratory morbidity, increased oxidant stress, and reduced nitric oxide production.
developing lungs. Beyond supportive care, there is a role for PH-specific pharmacotherapy in the right clinical situation, 5, 6 though continued research is needed.
As the population of ELGANs with PH grows, there is a need to better characterize the phenotype of infants with this comorbidity so that earlier identification and intervention can occur. Current evidence indicates that a diagnosis of bronchopulmonary dysplasia (BPD) associates with increased risk of developing PH 7 and that these infants have increased length of stay in the neonatal intensive care unit (NICU). 8 There is also a need for early biomarkers that predict the development of PH, as such biomarkers have the potential to provide time for intervention prior to PH development.
The Prematurity and Respiratory Outcomes Program (PROP) was a prospective multi-center observational trial of premature infants born between 23 and 29 weeks gestational age. [9] [10] [11] Clinical parameters as well as biological samples were collected from the infants in a prospective manner with the main objective being to better understand long-term respiratory morbidity in this population. The PROP cohort presents a unique opportunity to study a well phenotyped cohort of ELGANs followed over time.
This study is a retrospective analysis of features of PH determined from clinical echocardiograms obtained at 36 weeks gestational age from the infants enrolled in PROP at our center. These echocardiographic features of PH, determined by a blinded external review of each study, were then associated with clinical parameters and biologic markers that were prospectively collected during the PROP study.
| METHODS

| Study design
The Improving Prematurity-Related Respiratory Outcomes at Vanderbilt (IMPROV) (U01HL101456) was a prospective observational study that was part of the multi-center Prematurity and Respiratory
Outcomes Program (PROP; U01 HL101794). 9 The main objective of this study was to evaluate longitudinal respiratory outcomes, up to 1 year corrected age, for extremely low gestational infants (ELGANS) in an effort to better understand the mechanistic and therapeutic targets of neonatal lung disease in this population. For the IMPROV cohort, in addition to the prospective collection of clinical data, biological samples were also collected four times in the first month of life for biomarker analysis and association with clinical parameters. The study was approved by the Vanderbilt IRB (#110833) and is listed in clinicaltrials.gov (NCT 01435187). All infants in this study were enrolled at Vanderbilt. The study protocol, including a review of information that would be collected, was discussed with parents of qualifying infants who met the inclusion and exclusion criteria.
Informed consent was obtained from at least one parent.
For this study, echocardiographic images were obtained from the Xcelera database, which is part of the medical record. These images were obtained from infants enrolled in IMPROV who had echocardiograms obtained for clinical purposes at 36 weeks corrected gestational age (±1 week). There were no study-specific criteria for obtaining the echocardiograms. Echocardiograms were blindly read by a single pediatric cardiologist, specifically evaluating the images for features of PH and other irregularities, as outlined in 
| Participants
Full inclusion and exclusion criteria for PROP have been previously described. 9 Briefly inclusion criteria included a gestational age between 23 0/7 and 28 6/7 weeks of gestation and less than 7 days of age at time of enrollment. Exclusion criteria included structurally significant congenital heart disease (not including patent ductus arteriosus and hemodynamically insignificant ventricular septal defect or atrial septal defect), structural abnormalities of the lung, and congenital malformations or syndromes expected to adversely affect life expectancy.
| Clinical endpoints
Clinical markers of respiratory status while in the NICU included days on mechanical ventilation, days on non-invasive ventilation (not intubated), and days with supplemental oxygen support by nasal cannula. These markers were obtained from the IMPROV database as well as chart review of the individual participants. In addition, birth weight, gestational age, weight gain per day, and length of stay in the NICU were gathered from the prospective IMPROV clinical database.
Additional measures of respiratory status included: BPD defined as failing a room-air (RA) challenge at 36 weeks gestational age as previously described, 9 and postprematurity respiratory disease (PRD) at 1 year as defined by Keller et al. 11 All biomarker data were stored in a REDCap (research electronic data capture) database.
| Biochemical markers
Samples for all plasma and urinary biochemical markers were obtained at time of enrollment (median of 3 days of life), 7, 14, and 28 days of life (±2 days). Selected markers of inflammation included plasma isoprostane and isofuran levels. These markers specifically represent oxidant stress, as they are byproducts of lipid peroxidation.
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Isoprostane and isofuran levels were determined in the Vanderbilt Eicosanoid Core Laboratory by methods previously described.
Nitric oxide metabolites (NOx), specifically nitrite and nitrate, were analyzed from urine specimens and corrected for urine creatinine. Urine NO X concentrations were measured by chemiluminescence analysis as previously described. 13 In brief, urine samples was carried into the analyzer using a constant flow of N 2 gas via a gas bubble trap containing 1 M NaOH to remove HCl vapor. A standard curve was generated by adding known amounts of NaNO 3 to distilled water and assaying as described for the urine samples.
Plasma amino acid profiles were quantified in Vanderbilt's clinical chemistry laboratory using a standard CLIA-approved method on a Hitachi 8800 amino acid analyzer. Amino acid levels were measured in batches using a plasma sample of 30 μL.
| Statistical considerations
Continuous variables were summarized using the median with upper and lower quartiles and categorical variables were summarized using percentages. Changes in biomarkers over Mild PH correlates to about half systemic RVP, moderate is half to three-fourth systemic RVP and severe is systemic RVP. Seven infants were classified as having mild PH and four infants classified as having moderate PH (Table 1) . No infants were classified as having severe PH.
Due to lack of complete envelope of the tricuspid regurgitation (TR) jet in all cases in which TR was present, classification of severity of PH was mostly based on the geometry of the interventricular septum.
| Participants and clinical features
The basic demographics and clinical features for the 60 infants who had an echocardiogram at 36 weeks corrected GA did not reveal any Tables S1 and S2 ).
| Biochemical markers
Of the 60 participants with echocardiographic data, 78% had biomarker specimens collected at all four prespecified time points.
Using ordinal logistic regression, there was no evidence that an increase in plasma isoprostances or isofurans were associated with PH severity at any time point (no PH, n = 49; mild PH, n = 7; or moderate PH, n = 4; Table 5 ). Each model used a multiplicative scale for isoprostane or isofuran exposure and are interpreted as the relative odds of more severe PH comparing subjects differing in exposure by a factor of two. Analyzed by odds ratios relative to doubling in respective levels, there were no statistical differences at any time point for either plasma isoprostanes or isofuran levels by PH status.
Using a similar approach, the estimated odds ratios for a doubling of levels of the selected components of the nitric oxide pathway (urine NOx, plasma arginine, plasma citrulline, and the arginine: ornithine + citrulline ratio) were analyzed (Table 6 ). Urine NOx levels were corrected for urine Cr. The median urine Cr values for each of the four time points (enrollment, day 7, 14, and 28) were similar: 0.09, 0.12, 0.1, protective. That is, comparing two subjects who differ in their citrulline level at day 7 by a factor of 2, the subject with a higher citrulline levels is 3.44 times less likely to develop more severe PH (having a higher outcome category of PH). None of these infants with PH were receiving inhaled nitric oxide therapy at the time of these observations.
Within-subject changes in NOx and citrulline levels over time in subjects with PH (n = 11) and without PH (n = 49) are shown in Supplement Figure S2 . 4 This recommendation comes from the previously referenced observations 12,13 that a diagnosis of BPD is associated with changes in lung development, specifically decreased alveolarization, and decreased pulmonary vascular growth, which is associated with an increased risk of PH in this premature infant population. However, our A limitation of this study is that the echocardiograms were not obtained prospectively as part of the parent observational study.
| DISCUSSION
Rather, the echocardiograms used in this study were ordered by the clinician for various reasons, which were retrospectively analyzed in a blinded manner. We realize that an additional limitation is selection bias in that only 60 of 172 infants had an echocardiogram at 36 weeks corrected GA and it is possible that if this selection bias was not present we may have seen different associations between PH and respiratory morbidity. To address this possible bias we performed a supplementary analysis. Overall, the infants who had an echocardiogram at 36 weeks corrected GA were similar to those infants who did not, with the exceptions being that infants who had an echocardiogram spent more days on supplemental oxygen via nasal cannula and these infants were also more likely to fail the RA challenge (Supplement Table S2 ). It is possible that the presence of hypoxemia prompted the clinician to consider PH evaluation with an echocardiogram.
It is conceivable that infants without available echocardiograms had subclinical PH, or went on to develop PH. While the incidence of PH in our cohort was similar to other studies, the overall small number of infants with PH in this cohort (n = 11),
could have resulted in a failure to identify differences in respiratory morbidity between the two groups of our study. In addition, none of the infants had a cardiac catheterization to validate the echocardiogram findings, though this is not uncommon in the premature infant population. Future studies investigating clinical features and biomarkers for PH in the ELGANs population should 
